Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589885 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT03589885 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT03589885, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
Interventions
- DRUG Placebo 2 mL auto-injector
- DRUG Placebo 1 mL prefilled syringe
- DRUG Secukinumab 2 mL auto-injector
- DRUG Secukinumab 1 mL prefilled syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2020-08-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03589885
The ClinicalTrials.gov registry entry for NCT03589885 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo 2 mL auto-injector is the first listed.
NCT03589885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03589885 about?
NCT03589885 is a clinical study titled "Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis". The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
What is the current status of trial NCT03589885?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2018-12-19. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT03589885?
The interventions under investigation include: Placebo 2 mL auto-injector (DRUG), Placebo 1 mL prefilled syringe (DRUG), Secukinumab 2 mL auto-injector (DRUG), Secukinumab 1 mL prefilled syringe (DRUG).
Who is sponsoring clinical trial NCT03589885?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.